• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Fujisawa to sell generics business

Article

Pharmaceutical developer Fujisawa USA of Deerfield, IL, announced March 31 that it is selling its generics business to American Pharmaceutical Partners of Santa Monica, CA. Fujisawa plans to retain its proprietary drug business, which includes the

Pharmaceutical developer Fujisawa USA of Deerfield, IL, announced March 31 that it is selling its generics business to American Pharmaceutical Partners of Santa Monica, CA. Fujisawa plans to retain its proprietary drug business, which includes the cardiac stress agent Adenoscan and cardiac therapy drug Adenocard. Both products are licensed from Medco Research of Research Triangle Park, NC. Fujisawa expects to complete the sale of its generics business by May. At that point, Fujisawa will restructure its remaining proprietary pharmaceutical business as a new corporate entity, Fujisawa Healthcare.

Recent Videos
Pertinent Insights into the Imaging of Patients with Marfan Syndrome
What New Brain MRI Research Reveals About Cannabis Use and Working Memory Tasks
Current and Emerging Legislative Priorities for Radiology in 2025
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 2
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 2
How Will the New FDA Guidance Affect AI Software in Radiology?: An Interview with Nina Kottler, MD, Part 1
A Closer Look at the New Appropriate Use Criteria for Brain PET: An Interview with Phillip Kuo, MD, Part 1
Teleradiology and Breast Imaging: Keys to Facilitating Personalized Service, Efficiency and Equity
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 3
Current and Emerging Insights on AI in Breast Imaging: An Interview with Mark Traill, MD, Part 2
Related Content
© 2025 MJH Life Sciences

All rights reserved.